SIGA

SIGA Technologies, Inc. - 10-Q Summary (Quarter Ended June 30, 2006)

Business Context and Reporting Period

SIGA Technologies, Inc. is a bio-defense company focused on the discovery and development of products against biological warfare agents (e.g., Smallpox, Arenaviruses) and novel anti-infectives. The company has no commercial products and relies on government grants and strategic alliances for funding. This report covers the three and six months ended June 30, 2006.

Key Financial Metrics

Note: The company reported a negative stockholders' equity position of approximately $757,000 as of June 30, 2006, compared to positive equity of $3.2 million at year-end 2005.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased by approximately 14% ($470,000) compared to the prior six-month period. This was primarily due to a $1.7 million decrease in NIH SBIR grant revenue, partially offset by $1.2 million in revenue from a new U.S. Army contract (USAMRMC).
• Increased Expenses: Selling, general, and administrative (SG&A) expenses rose 47% to $2.4 million. This increase was driven by professional fees ($635,000) related to a potential merger with PharmAthene, Inc. (PHTN), a non-cash consulting charge of $217,000, and the adoption of SFAS 123(R) share-based compensation ($184,000).
• Debt Financing: The company issued three 8% bridge notes totaling $3.0 million to PHTN to fund operations and the merger process. This significantly increased current liabilities.
• Derivative Liability Loss: A non-cash loss of $1.1 million was recorded due to the increase in the fair market value of common stock rights and warrants issued in late 2005.

Outlook, Risks, and Management Commentary

• Merger with PHTN: On June 8, 2006, SIGA entered into a Merger Agreement with PharmAthene, Inc. PHTN stockholders will receive approximately 68% of the combined company. The merger is contingent on stockholder approval and the sale of at least $25 million of SIGA equity securities.
• Liquidity: Management believes existing cash ($3.1 million) and anticipated cash flows from government contracts will support operations beyond June 30, 2007. However, the company has incurred cumulative losses and expects to incur additional losses.
• NASDAQ Compliance Risk: On July 19, 2006, SIGA received notice from NASDAQ that it failed to meet the minimum market value of listed securities ($35 million) and minimum stockholders' equity ($2.5 million) requirements. The company has 30 days (until August 18, 2006) to regain compliance or face delisting.
• Product Development: The lead product, SIGA-246 (Smallpox antiviral), is in Phase I clinical trials. Estimated costs to complete the program range from $15 million to $20 million over 12 to 36 months.
• Legal Proceedings: A lawsuit filed by Four Star Group alleges breach of contract and tortious interference, seeking damages in excess of $700,000. SIGA intends to contest the claims vigorously.

Investor Verification Checklist

• NASDAQ Delisting Status: Verify if the company regained compliance with NASDAQ listing rules by August 18, 2006, or if delisting proceedings were initiated.
• Merger Completion: Confirm whether the merger with PharmAthene, Inc. was consummated and if the required $25 million equity financing was secured.
• Cash Burn Rate: Monitor the rate of cash consumption against the $3.1 million cash balance to assess the runway for operations beyond mid-2007.
• Debt Covenants: Review the terms of the $3 million bridge notes to PHTN, specifically regarding maturity dates and acceleration clauses upon default.
• Grant Funding: Verify the status of NIH SBIR grants and the USAMRMC contract, as these remain critical revenue sources.